Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avail Study
NCT06465108Phase 2Completed
- Sponsor
- MBX Biosciences, Inc.
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 3
01
Overview
A Phase 2 trial of canvuparatide in hypoparathyroidism, sponsored by MBX Biosciences, Inc.. Started Aug 2024; status: completed.
02
Drugs
canvuparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT06465108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465108.